科濟藥業-B(02171.HK):舒瑞基奧侖賽注射液用於治療晚期胃╱食管胃結合部腺癌的中國關鍵II期臨牀試驗取得初步陽性結果
格隆匯12月30日丨科濟藥業-B(02171.HK)發佈公吿,關鍵II期臨牀試驗CT041-ST-01(NCT04581473) 已取得陽性結果。該試驗是一項在中國進行的隨機對照、多中心的臨牀試驗,旨在評估舒瑞基奧侖賽注射液(研發代碼:CT041,一種靶向Claudin18.2自體 CAR-T細胞候選產品)治療Claudin18.2表達陽性、既往接受過至少2線治療失敗的晚期胃╱食管胃結合部腺癌的有效性和安全性,受試者以2:1的比例隨機分配至舒瑞基奧侖賽注射液組或研究者選擇治療組(包括紫杉醇、多西他賽、伊立替康、阿帕替尼或納武利尤單抗)。該試驗的主要終點為由獨立評審委員會(IRC)評價的無進展生存期(PFS)。該試驗主要終點已達成,即:與研究者選擇治療組相比,舒瑞基奧侖賽注射液組中的受試者的無進展生存期具有統計學意義上的顯著改善。既往試驗數據表明,該產品安全性可控。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.